Description

Book Synopsis


Table of Contents
SECTION 1 The world of RNA therapeutics: Available RNA tools to modulate cellular processes 1. Targeting chromatin: Transcriptional gene activation (saRNA) 2. Argonaute and TNRC6, partners in RNAi 3. Targeted RNA therapeutics for treatment of cancer and immunomodulation 4. Extrahepatic delivery of RNA to immune cells SECTION 2 Learning from history 5. Aptamer-based protein inhibitors 6. Lessons learned from developing an oligonucleotide drug for a rare disease SECTION 3 Delivery 7. Nucleoside modifications of in vitro transcribed mRNA to reduce immunogenicity and improve translation of prophylactic and therapeutic antigens 8. SOMAmer reagents and the SomaScan platform: Chemically modified aptamers and their applications in therapeutics, diagnostics, and proteomics SECTION 4 From bench to bedside 9. CMC and regulatory aspects of oligonucleotide therapeutics 10. CMC: Regulatory landscape 11. CMC and manufacturing SECTION 5 From bench to bedside 12. RNA delivery for cancer gene therapy 13. Combinatorial RNA therapies in cancer immunotherapy: Challenges and directions

RNA Therapeutics

Product form

£130.50

Includes FREE delivery

RRP £145.00 – you save £14.50 (10%)

Order before 4pm today for delivery by Wed 17 Dec 2025.

A Paperback by Paloma H. Giangrande, Vittorio de Franciscis, John J. Rossi

Out of stock


    View other formats and editions of RNA Therapeutics by Paloma H. Giangrande

    Publisher: Elsevier Science
    Publication Date: 4/13/2022 12:00:00 AM
    ISBN13: 9780128215951, 978-0128215951
    ISBN10: 012821595X
    Also in:
    Science & Nature Molecular biology

    Description

    Book Synopsis


    Table of Contents
    SECTION 1 The world of RNA therapeutics: Available RNA tools to modulate cellular processes 1. Targeting chromatin: Transcriptional gene activation (saRNA) 2. Argonaute and TNRC6, partners in RNAi 3. Targeted RNA therapeutics for treatment of cancer and immunomodulation 4. Extrahepatic delivery of RNA to immune cells SECTION 2 Learning from history 5. Aptamer-based protein inhibitors 6. Lessons learned from developing an oligonucleotide drug for a rare disease SECTION 3 Delivery 7. Nucleoside modifications of in vitro transcribed mRNA to reduce immunogenicity and improve translation of prophylactic and therapeutic antigens 8. SOMAmer reagents and the SomaScan platform: Chemically modified aptamers and their applications in therapeutics, diagnostics, and proteomics SECTION 4 From bench to bedside 9. CMC and regulatory aspects of oligonucleotide therapeutics 10. CMC: Regulatory landscape 11. CMC and manufacturing SECTION 5 From bench to bedside 12. RNA delivery for cancer gene therapy 13. Combinatorial RNA therapies in cancer immunotherapy: Challenges and directions

    Recently viewed products

    © 2025 Book Curl

      • American Express
      • Apple Pay
      • Diners Club
      • Discover
      • Google Pay
      • Maestro
      • Mastercard
      • PayPal
      • Shop Pay
      • Union Pay
      • Visa

      Login

      Forgot your password?

      Don't have an account yet?
      Create account